Eledon Pharma (NASDAQ: ELDN)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.680 | -0.690 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eledon Pharma (NASDAQ: ELDN) through any online brokerage.
Other companies in Eledon Pharma’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Virios Therapeutics (NASDAQ:VIRI), Cabaletta Bio (NASDAQ:CABA), Brooklyn (NASDAQ:BTX) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Eledon Pharma (NASDAQ: ELDN) was reported by HC Wainwright & Co. on Wednesday, November 24, 2021. The analyst firm set a price target for 25.00 expecting ELDN to rise to within 12 months (a possible 681.25% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Eledon Pharma (NASDAQ: ELDN) is $3.2 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for Eledon Pharma.
Eledon Pharma’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Eledon Pharma.
Eledon Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.